Dec 27, 2021

The expression of major histocompatibility complex class I (MHC I) has previously been reported to be negatively associated with estrogen receptor (ER) expression. Furthermore, MHC I expression, level...

Dec 20, 2021

This study aimed to evaluate the effect of bladder wall thickness (BWT) (using transabdominal ultrasound) on the outcomes of antimuscarinic treatment in women with overactive bladder.A total of 102 fe...

Dec 20, 2021

In 54 participants (41% women) from the Czech arm of the European Longitudinal Study of Pregnancy and Childhood, a national birth cohort with prospectively collected data from their birth until young ...

Dec 20, 2021

the aim of this study was to determine whether maternal serum IL-6 and postnatal melatonin levels change with the mode of delivery.a prospective controlled study was performed on pregnant women (17-43...

Dec 20, 2021

The aim of the study was to determine the risk of distant metastases in patients with gynecologic cancers after surgery, including cervical, uterine and ovarian cancers. This is a retrospective study ...

Dec 20, 2021

Endometriosis (EDT), a common estrogen-dependent inflammatory disorder, is characterized by endometrial-like tissue outside the uterus. While its pathogenesis is poorly understood, it is supposed that...

Dec 15, 2021

In three MONALEESA phase 3 trials, addition of ribociclib to adjuvant endocrine therapy improved overall survival (OS) in post-menopausal patients with locally advanced/metastatic HR-positive/HER2-neg...

Dec 15, 2021

According to the first results of the EMERALD trial, elacestrant, the first oral selective estrogen receptor degrader, shows clinical benefit over standard endocrine therapy in patients with ER-positi...

Dec 15, 2021

Primary analysis of the KEYNOTE-522 trial shows a statistically significant and clinically meaningful improvement in the event-free survival (EFS) of neoadjuvant pembrolizumab plus chemotherapy follow...

Dec 15, 2021

A next-generation technology allows the study of protein expression at the single-cell level and the location of the cells within the tumor microenvironment (TME). In the NeoTRIPaPDL1 trial, it provid...

Dec 15, 2021

Although adjuvant therapy with CDK4/6 inhibitors has shown to benefit patients with advanced/metastatic HR-positive/HER2-negative breast cancer, the final analysis of the PALLAS trial shows no benefit...

Dec 15, 2021

The use of multigene sequencing as a therapeutic decision tool improved the outcomes for patients with metastatic breast cancer when the genomic alterations identified were ranked in the I/II tiers of...

Dec 15, 2021

The pathways leading to CDK4/6 inhibitor resistance are not yet clear. Using a technique called ‘accelerated mutagenesis’, researchers unraveled the role of ASXL1 loss. Initial findings in ER-posi...

Dec 15, 2021

Development of breast cancer-related lymphedema is not equally distributed between races. Black women experienced higher rates of breast cancer-related lymphedema than White women, results of a prospe...

Dec 15, 2021

Efficacy of second-line treatment option for patients with ER-positive/HER2-negative metastatic breast cancer who progress on an aromatase inhibitor plus CDK4/6 inhibitor is poor. In a first-in-human ...

Dec 15, 2021

The phase 3 BioItaLEE trial demonstrates that pre-treatment circulating tumor DNA (ctDNA) and early dynamics of ctDNA represent promising prognostic and predictive biomarkers in patients with HR-posit...

Dec 15, 2021

Adjuvant treatment with the PARP inhibitor olaparib showed beneficial effects for patients with BRCA1/2 mutations and high-risk, HER2-negative, early-stage, primary breast cancer. In addition, patient...

Dec 15, 2021

Both patients with heavily pre-treated HR-positive/HER2-negative, HER2-mutated, metastatic breast cancer and patients with heavily pre-treated HER2-mutated metastatic triple-negative breast cancer (TN...

Dec 15, 2021

Long-term use of tamoxifen is associated with an increased risk for the development of uterine cancer. New research shows that tamoxifen directly activates a signaling pathway (PIK3) that is a well-kn...

Dec 15, 2021

In pre-menopausal women with early-stage, ER-positive breast cancer, adjuvant ovarian suppression can be combined with tamoxifen or an aromatase inhibitor. A meta-analysis of 4 randomized controlled t...